Undisclosed oral peptide dual agonist / Pfizer, D&D Pharmatech - LARVOL DELTA

D&D Pharmatech, a Korean company specializing in GLP-1 drugs, said Thursday that it has signed a research service contract with Pfizer to develop an oral peptide dual agonist for obesity treatment (Korea Biomedical Review) - "The confirmed contract amount is $1.24 million (1.83 billion won). The target contract period runs from April 14 to Nov. 30, although the company said the actual duration will extend until all payments are completed. D&D Pharmatech will conduct manufacturing and supply in-house. The payment will be made within 90 days after the completion of each research service item."

Licensing / partnership • Obesity